Abstract
Prior research has widely recognized neurocognitive impairment (NCI), depression, and alcohol use disorders (AUDs) as important negative predictors of health-related quality of life (HRQoL) among people living with HIV (PLWH). No studies to date, however, have explored how these neuropsychological factors operate together and affect HRQoL. Incarcerated male PLWH (N = 301) meeting criteria for opioid dependence were recruited from Malaysia’s largest prison. Standardized scales for NCI, depression, alcohol use disorders (AUDs) and HRQoL were used to conduct a moderated mediation model to explore the extent to which depression mediated the relationship between NCI, HRQoL, and AUDs using an ordinary least squares regression-based path analytic framework. Results showed that increasing levels of NCI (B = −0.1773, p < 0.001) and depression (B = −0.6147, p < 0.001) were negatively associated with HRQoL. The effect of NCI on HRQoL was significantly (Sobel z = −3.5600, p < 0.001) mediated via depression (B = −0.1230, p < 0.001). Furthermore, the conditional indirect effect of NCI on HRQoL via depression for individuals with AUDs was significant (B = −0.9099, p = 0.0087), suggesting a moderated mediation effect. The findings disentangle the complex relationship using a moderated mediation model, demonstrating that increasing levels of NCI, which can be reduced with HIV treatment, negatively influenced HRQoL via depression for individuals with AUDs. This highlights the need for future interventions to target these complex interplay between neuropsychological factors in order to improve HRQoL among PLWH, particularly incarcerated PLWH with AUDs.
Similar content being viewed by others
References
Dolan K, Wirtz A, Moazen B, Galvani AP, Ndeffo Mbah ML, Kinner S, et al. Global Burden of HIV, viral hepatitis and tuberculosis among prisoners and detainees. Lancet. 2016, (In press).
Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Geneva, 2016. Accessed 28 May 2016: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006;24:751–65.
Johnson M, Samarina A, Xi H, Valdez Ramalho Madruga J, Hocqueloux L, Loutfy M, et al. Barriers to access to care reported by women living with HIV across 27 countries. AIDS Care. 2015;27:1220–30.
Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: the public health perspective. Am J Public Health. 2012;102:1516–26.
Basavaraj KH, Navya MA, Rashmi R. Quality of life in HIV/AIDS. Indian J Sex Transm Dis. 2010;31:75–80.
UNAIDS. The gap report. UNAIDS; 2014. Accessed 27 May 2016: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.
Ngadiman S, Suleiman A, Taib SM, Yuswan F. Malaysia 2014: Country responses to HIV/AIDS. Malaysia: Ministry of Health Malaysia; 2014. Accessed 28 May 2016: http://www.unaids.org/sites/default/files/country/documents//MYS_narrative_report_2014.pdf.
Bazazi A, Crawford F, Zelenev A, Heimer R, Kamarulzaman A, Altice FL. HIV prevalence among people who inject drugs in Greater Kuala Lumpur recruited using respondent-driven sampling. AIDS Behav. 2015;19:2347–57.
Zahari MM, Hwan Bae W, Zainal NZ, Habil H, Kamarulzaman A, Altice FL. Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia. Am J Drug Alcohol Abuse. 2010;36:31–8.
Bachireddy C, Bazazi AR, Kavasery R, Govindasamy S, Kamarulzaman A, Altice FL. Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend. 2011;116:151–7.
Choi P, Kavasery R, Desai MM, Govindasamy S, Kamarulzaman A, Altice FL. Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia. Int J STD AIDS. 2010;21:416–23.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45.
Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376:355–66.
Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res. 2009;15:107–12.
Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, et al. Accessing antiretroviral therapy following release from prison. JAMA. 2009;301:848–57.
Festa L, Meucci O. Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism. Curr HIV Res. 2012;10:453–62.
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37:209–18.
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence and the criminal justice system: a review and call for evidence-based treatment. Am J Drug Alcohol Abus. 2011;37:12–21.
Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS ONE. 2013;8:e59643.
Scheyett A, Parker S, Golin C, White B, Davis CP, Wohl D. HIV-infected prison inmates: depression and implications for release back to communities. AIDS Behav. 2010;14:300–7.
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38:1754–60.
Stephenson BL, Wohl DA, Golin CE, Tien H-C, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120:84–8.
Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14:1213–26.
Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.
Albert SM, Marder K, Dooneief G, Bell K, Sano M, Todak G, et al. Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol. 1995;52:525–30.
Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56:1004–17.
Villa G, Solida A, Moro E, Tavolozza M, Antinori A, De Luca A, et al. Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol. 1996;36:125–33.
van Gorp WG, Baerwald JP, Ferrando SJ, McElhiney MC, Rabkin JG. The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc. 1999;5:534–9.
Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol. 2001;58:473–9.
Bates ME, Bowden SC, Barry D. Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol. 2002;10:193–212.
Shrestha R, Huedo-Medina TB, Copenhaver MM. Sex-related differences in self-reported neurocognitive impairment among high-risk cocaine users in methadone maintenance treatment program. Subst Abus. 2015;9:17–24.
Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci. 2007;8:141–51.
Ferro EG, Weikum D, Vagenas P, Copenhaver MM, Gonzales P, Peinado J, et al. Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care. 2014;1–12.
Weikum D, Ferro EG, Shrestha R, Vagenas P, Copenhaver MM, Spudich S, et al. Neurocognitive impairment negatively influences antiretroviral medication adherence among men who have sex with men in Peru. AIDS & Behavior. 2016 (Under review).
Huedo-Medina TB, Shrestha R, Copenhaver M. Modeling a theory-based approach to examine the influence of neurocognitive impairment on HIV risk reduction behaviors among drug users in treatment. AIDS and Behavior. 2016;1–12.
Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.
Jin H, Hampton Atkinson J, Yu X, Heaton RK, Shi C, Marcotte TP, et al. Depression and suicidality in HIV/AIDS in China. J Affect Disord. 2006;94:269–75.
Kagee A, Martin L. Symptoms of depression and anxiety among a sample of South African patients living with HIV. AIDS Care. 2010;22:159–65.
Dal-Bo MJ, Manoel AL, Filho AO, Silva BQ, Cardoso YS, Cortez J, et al. Depressive symptoms and associated factors among people living with HIV/AIDS. J Int Assoc Provid AIDS Care. 2015;14:136–40.
Tate D, Paul RH, Flanigan TP, Tashima K, Nash J, Adair C, et al. The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care STDS. 2003;17:115–20.
Jia H, Uphold CR, Wu S, Chen GJ, Duncan PW. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS. 2005;19:395–405.
Charles B, Jeyaseelan L, Pandian AK, Sam AE, Thenmozhi M, Jayaseelan V. Association between stigma, depression and quality of life of people living with HIV/AIDS (PLHA) in South India–a community based cross sectional study. BMC Public Health. 2012;12:463.
Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS. 2004;15:254–9.
Osowiecki DM, Cohen RA, Morrow KM, Paul RH, Carpenter CCJ, Flanigan T, et al. Neurocognitive and psychological contributions to quality of life in HIV-1-infected women. AIDS. 2000;14:1327–32.
Adewuya AO, Afolabi MO, Ola BA, Ogundele OA, Ajibare AO, Oladipo BF, et al. Relationship between depression and quality of life in persons with HIV infection in Nigeria. Int J Psychiatry Med. 2008;38:43–51.
Rosenbloom MJ, Sullivan EV, Sassoon SA, O’reilly A, Fama R, Kemper CA, et al. Alcoholism, HIV infection, and their comorbidity: factors affecting self-rated health-related quality of life. J Stud Alcohol Drugs. 2007;68:115–25.
Tran BX, Nguyen LT, Do CD, Nguyen QL, Maher RM. Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC Public Health. 2014;14:1–7.
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend. 2013;132:378–82.
Wickersham JA, Marcus R, Kamarulzaman A, Zahari MM, Altice FL. Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ. 2013;91:124–9.
Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health psychol. 2003;22:223–8.
Brislin RW. Back-translation for cross-cultural research. J Cross-Cult Psychol. 1970;1:185–216.
Shrestha R, Karki P, Heudo-Medina T, Copenhaver M. Treatment engagement moderates the effect of neurocognitive impairment on antiretroviral therapy adherence among HIV-infected drug users in treatment. J Assoc Nurses AIDS Care. 2016, (Under review).
Copenhaver M, Shrestha R, Wickersham JA, Weikum D, Altice FL. An exploratory factor analysis of a brief self-report scale to detect neurocognitive impairment among participants enrolled in methadone maintenance therapy. J Subst Abus Treat. 2016.
Shrestha R, Weikum D, Copenhaver M, Altice F. A self-report measure to detect neurocognitive impairment among incarcerated people living with HIV in Malaysian context: an exploratory factor analysis. PLoS One. 2016, (Under review).
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
Cook JA, Cohen MH, Burke J, Grey D, Anastos K, Kirstein L, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401–9.
Low-Beer S, Chan K, Yip B, Wood E, Montaner JS, O’Shaughnessy MV, et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr. 2000;23:295–301.
Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. 2001; 2.
Hays RD, Sherbourne CD, Mazel RM. The rand 36-item health survey 1.0. Health Econ. 1993;2:217–27.
Baron RM, Kenny DA. The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51:1173.
Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS (Auckland, N.Z.). 2012;4:117–24.
McInerney PA, Ncama BP, Wantland D, Bhengu BR, McGibbon C, Davis SM, et al. Quality of life and physical functioning in HIV-infected individuals receiving antiretroviral therapy in KwaZulu-Natal, South Africa. Nursing & Health Sciences. 2008;10:266–72.
Safren SA, Hendriksen ES, Smeaton L, Celentano DD, Hosseinipour MC, Barnett R, et al. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav. 2012;16:266–77.
Igumbor J, Stewart A, Holzemer W. Comparison of the health-related quality of life, CD4 count and viral load of AIDS patients and people with HIV who have been on treatment for 12 months in rural South Africa. SAHARA J. 2013;10:25–31.
Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. Guilford Press; 2013.
Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol. 1982;13:290–312.
Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior research methods. 2008;40:879–91.
MacKinnon DP, Lockwood CM, Williams J. Confidence limits for the indirect effect: distribution of the product and resampling methods. Multivar Behav Res. 2004;39:99.
Bollen KA, Stine R. Direct and indirect effects: classical and bootstrap estimates of variability. Sociol Methodol. 1990;20:15–140.
Hayes AF. An index and test of linear moderated mediation. Multivar Behav Res. 2015;50:1–22.
Preacher KJ, Rucker DD, Hayes AF. Addressing moderated mediation hypotheses: theory, methods, and prescriptions. Multivar Behav Res. 2007;42:185–227.
Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS. 2004;15:254–9.
Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS patient care STDs. 2013;27:5–16.
Mitchell AJ, Kemp S, Benito-León J, Reuber M. The influence of cognitive impairment on health-related quality of life in neurological disease. Acta Neuropsychiatrica. 2010;22:2–13.
Sherbourne CD, Hays RD, Fleishman JA, Vitiello B, Magruder KM, Bing EG, et al. Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry. 2000;157:248–54.
Korthuis PT, Zephyrin LC, Fleishman JA, Saha S, Josephs JS, McGrath MM, et al. Health-related quality of life in HIV-infected patients: the role of substance use. AIDS Patient Care STDs. 2008;22:859–67.
Nakasujja N, R Skolasky L, Musisi S, Allebeck P, Robertson K, Ronald A, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry. 2010;10:1–7.
Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: results from the Steps Study. AIDS Behav. 2011;15:1161–70.
Althoff AL, Zelenev A, Meyer JP, Fu J, Brown SE, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2013;17(Suppl 2):S156–70.
Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. Lancet HIV. 2014;1:e77–84.
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174:721–9.
Springer SA, Spaulding A, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis. 2011;53:469–79.
Funding
This work was supported by Grants from the National Institute on Drug Abuse for research (R01 DA025943 to FLA) and for career development (K24 DA017072 to FLA; K02 033139 to MMC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors have no conflicts of interest to disclose.
Ethical approval
Institutional review boards at the University Malaya Medical Centre and Yale University approved the protocol for the parent study. The protocol was also reviewed and approved by the Office of Human Research Protection at the US Department of Health and Human Services (DHHS) as it involved federally-funded research with prisoners. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Shrestha, R., Weikum, D., Copenhaver, M. et al. The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. AIDS Behav 21, 1070–1081 (2017). https://doi.org/10.1007/s10461-016-1526-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-016-1526-3